<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04107987</url>
  </required_header>
  <id_info>
    <org_study_id>P-20180017962</org_study_id>
    <nct_id>NCT04107987</nct_id>
  </id_info>
  <brief_title>Berberine, Curcumin, Inositol, Banaba and Chromium Picolinate in Patients With Fasting Dysglycemia</brief_title>
  <official_title>An Evaluation of a Nutraceutical With Berberine, Curcumin, Inositol, Banaba and Chromium Picolinate in Patients With Fasting Dysglycemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pavia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pavia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dysglycemia is an important pre-risk condition which can potentially lead to diabetes if not
      adequately treated. The variation of glycemic balance can lead to cardiovascular disorders.
      The study will evaluate if Reglicem速, a nutraceutical containing Berberine, Curcumin,
      Inositol, Banaba, and Chromium Picolinate, can ameliorate glycemic status in patients with
      dysglycemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dysglycemia is an important pre-risk condition which can potentially lead to diabetes if not
      adequately treated. The variation of glycemic balance can lead to cardiovascular disorders.
      The study will evaluate if Reglicem速, a nutraceutical containing Berberine, Curcumin,
      Inositol, Banaba, and Chromium Picolinate, can ameliorate glycemic status in patients with
      dysglycemia.

      The investigators will enroll patients with impaired fasting glucose (IFG) or impaired
      glucose tolerance (IGT), not taking other hypoglycemic compounds. Patients will be randomized
      to take Reglicem速 or placebo for 3 months, in a randomized, double-blind, placebo-controlled
      design. Reglicem速 and placebo will be self-administered once a day, 1 tablet during the
      breakfast.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Actual">August 31, 2019</completion_date>
  <primary_completion_date type="Actual">August 31, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression of dysglicemia</measure>
    <time_frame>3 months</time_frame>
    <description>Oral glucose tolerance test</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">148</enrollment>
  <condition>Dysglycemia</condition>
  <arm_group>
    <arm_group_label>Reglicemi</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reglicemi is a nutraceutical containing Berberine, Curcumin, Inositol, Banaba, and Chromium Picolinate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Reglicem</intervention_name>
    <description>Reglicem is a nutraceutical containing Berberine, Curcumin, Inositol, Banaba, and Chromium Picolinate</description>
    <arm_group_label>Reglicemi</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with impaired fasting glucose (IFG) or impaired fasting glucose (IGT)

          -  Patients not taking hypoglycemic agents (both pharmaceuticals or nutraceutical agents)

        Exclusion Criteria:

          -  Patients with type 1 or type 2 diabetes mellitus

          -  Patients with impaired hepatic function

          -  Patient with impaired renal function

          -  Patients with gastrointestinal disorders

          -  Patients with current or previous evidence of ischemic heart disease, heart failure,
             or stroke

          -  Patients with weight change of &gt; 3 Kg during the preceding 3 months

          -  Patients with hystory of malignancy, and significant neurological or psychiatric
             disturbances, including alcohol or drug abuse.

          -  Patients taking (within the previous 3 months) hypoglycemic agents, laxatives,
             beta-agonists (other than inhalers), cyproheptadine, anti-depressants,
             antiserotoninergics, phenothiazines, barbiturates, oral corticosteroids, and
             antipsychotics

          -  Women who were pregnant or breastfeeding or of childbearing potential and not taking
             adequate contraceptive precautions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <state>Lombardia</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 25, 2019</study_first_submitted>
  <study_first_submitted_qc>September 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2019</study_first_posted>
  <last_update_submitted>September 27, 2019</last_update_submitted>
  <last_update_submitted_qc>September 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pavia</investigator_affiliation>
    <investigator_full_name>Giuseppe Derosa</investigator_full_name>
    <investigator_title>MD, PHd, FESC</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

